Intercure's decision to delist from the Toronto Stock Exchange is a strategic move that may not directly affect its NASDAQ-listed shares. The company will continue to be listed on the NASDAQ and TASE, which means that its shares will still be accessible to investors. Therefore, the short-term impact on its stock price is expected to be neutral.